About Axelyf
Axelyf, Inc. is a biotechnology company developing RNA therapeutics for oncology and autoimmune diseases. Headquartered in Massachusetts with subsidiary Axelyf ehf in Iceland, Axelyf combines deep expertise in lipid chemistry, RNA biology, and drug delivery science with an AI-driven design platform to build best-in-class medicines from the ground up.
By developing the AXL lipid nanoparticle platform internally and applying it to high-value therapeutic programs, Axelyf captures the full potential of its delivery science while maintaining the flexibility to partner its technology across the RNA medicine landscape.
Core Values
Excellence
We want the best possible science and R&D to happen, and we are obsessed with learning. The science of pharmaceutical R&D is often complex, and we need to strive for excellent work that can be interpreted clearly for the best possible learning each time.
Integrity
We want to do the right thing, always, even when it is hard to do or when no one is looking. Our collaborators, clinical professionals, and patients in the future, deserve nothing less from us.
Transparency
Our team is small, and we are open with one another. We work closely on challenging tasks and programs, so we need to be clear about the issues and stay solutions focused, together.
Investors
Brunnur Ventures
Brunnur Ventures is an Iceland-based early-stage venture capital firm investing in globally scalable technology and life-science companies. Its biotech track record includes an early investment in Oculis, a clinical-stage biopharmaceutical company dual-listed on Nasdaq NY and Nasdaq Iceland (OCS), where Árni Blöndal served on the board throughout the IPO process. Brunnur brings hands-on venture experience and long-term support for science-driven companies scaling internationally.
Omega VC
Omega is an Icelandic investment firm with a strong history in life sciences and medtech. It was the largest investor in Kerecis, where Andri Sveinsson served on the board until the company’s $1.3 billion acquisition by Coloplast. Omega contributes deep experience in building and exiting global biomedical companies.
Silfurberg
Silfurberg is an Icelandic healthcare and biotech investor founded by the creator of Invent Farma, a pharmaceutical company focused on drug development and manufacturing.
76Bio, Inc.
76Bio is a legacy biotechnology company focused on undruggable cancer targets, using protein degrader technology based on mRNA and lipid nanoparticles (LNP) and RNA delivery technologies. Axelyf acquired the assets of 76Bio, including a proprietary compound library originally developed in part by former Moderna mRNA-LNP experts, and has since expanded and protected the assets as part of its AXL technology platform. Investors of 76Bio remain strategic shareholders in the company.
Partner with Us
Axelyf is exploring co-development and licensing opportunities for the AXL lipid library across therapeutic areas. If you're interested in best-in-class RNA-LNP delivery for your programs, we'd like to hear from you. Contact us at info@axelyf.com.